Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.
Insider and Institutional Ownership
7.2% of Journey Medical shares are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Profitability
This table compares Collegium Pharmaceutical and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Collegium Pharmaceutical | 5.93% | 91.43% | 15.57% |
| Journey Medical | -8.95% | -20.23% | -6.60% |
Earnings & Valuation
This table compares Collegium Pharmaceutical and Journey Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Collegium Pharmaceutical | $808.21 million | 0.92 | $62.87 million | $1.24 | 18.48 |
| Journey Medical | $68.18 million | 1.99 | -$11.43 million | ($0.22) | -21.82 |
Collegium Pharmaceutical has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Collegium Pharmaceutical and Journey Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Collegium Pharmaceutical | 1 | 1 | 6 | 1 | 2.78 |
| Journey Medical | 1 | 0 | 2 | 0 | 2.33 |
Collegium Pharmaceutical presently has a consensus target price of $48.71, indicating a potential upside of 112.54%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 191.67%. Given Journey Medical’s higher probable upside, analysts clearly believe Journey Medical is more favorable than Collegium Pharmaceutical.
Summary
Collegium Pharmaceutical beats Journey Medical on 10 of the 15 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
